Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527672 | 0.88 | CHRM4 (0.53) | CHRM4DRD4DRD2GRM5KDM4E | |
| SCHEMBL2341786 | 0.87 | HTR2A (0.44) | KMT2ADRD4DRD2GRM5ALDH1A1 | |
| SCHEMBL30163903 | 0.84 | CHRM4 (0.46) | CHRM4DRD4DRD2GRM5KDM4E | |
| SCHEMBL8222584 | 0.84 | CHRM4 (0.46) | CHRM4DRD4DRD2GRM5KDM4E | |
| SCHEMBL3605550 | 0.84 | AR (0.64) | AR | |
| SCHEMBL7522691 | 0.82 | PTPN1 (0.50) | CHRM4KMT2ADRD4DRD2PTPN1 | |
| SCHEMBL13622664 | 0.82 | FFAR4 (0.56) | CHRM4DRD4DRD2GRM5DRD3 | |
| SCHEMBL20140119 | 0.81 | GRM5 (0.49) | CHRM4KMT2ADRD4DRD2GRM5 | |
| SCHEMBL8006055 | 0.81 | PDCD1 (0.43) | CHRM4PTPN1C5AR1 | |
| SCHEMBL7519811 | 0.81 | CHRM4 (0.45) | CHRM4DRD4DRD2GRM5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6127541-A | 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0863144-A1 | IMIDAZOQUINAZOLINE DERIVATIVES | Kyowa Hakko Co., Ltd. (JP) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | MKI67, HRAS, VHL | CHRM4 4553/4885KMT2A 1337/4885DRD4 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.